DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc announces the FDA has granted priority review of the teprotumumab BLA for the treatment of active thyroid eye disease.
STAAR Surgical Announces EVO ICL Clinical Program for Its 16th Annual Surgical Experts Summit in Paris, France From September 11 – 13, 2019
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing the EVO ICL Clinical Program which will be…
Read OSN’s Sept. 10 publication exclusives online
The cover story in the Sept. 10 issue of Ocular Surgery News discusses retinal OCT before cataract surgery to help choose treatment options. Here are some of the publication exclusives from the issue: Cover StoryRetinal OCT before cataract surgery incr…
Santen microshunt study results lead news of the week
Here are some of the past week’s top stories on Healio.com/OSN: DE-128 microshunt reduced IOP, medications in studyA multicenter study found the DE-128 microshunt implanted intraoperatively with 0.2 mg/mL concentration of mitomycin C effectively reduce…
Ocular manifestations often present first in multiple sclerosis
COEUR D’ALENE, Idaho — There is a high frequency of ocular manifestations in patients with multiple sclerosis, both at onset and during the disease course, according to a poster presented at the Women in Ophthalmology Summer Symposium.In a retrospectiv…
Injectable Hydrogel for Transcatheter Intravascular Embolization: Interview with Dr. Rahmi Oklu, Founder of Obsidio
Obsidio Inc., a medical device company based in Columbia, South Carolina, has developed an embolic hydrogel (called a gel embolic material: GEM) designed to be delivered minimally invasively through a clinical catheter for blood vessel occlusion. Applications include controlling blood flow in vascular injuries and aneurysms, reducing tumor blood su (Read more...)